Triple-negative breast cancer, an aggressive type of breast cancer, accounts for 10% of all breast cancer cases in the United ...

Adding an immune checkpoint inhibitor (ICI) to chemotherapy for advanced prostate cancer failed to improve survival as ...

Approximately 80% of individuals who receive immune checkpoint inhibitors for advanced cancer do not respond to therapy, according to results of a cross-sectional analysis.The number of FDA-approved ...

Candel Therapeutics Inc. stock ended Wednesday deep in the red but rose 1.3% in extended trading after the company announced ...

Recently, the research team led by Professor Zhang Zhongtao and Professor Yao Hongwei from the General Surgery Center at ...

There were a number of notable developments for patients with kidney cancer at the symposium, Dr. Emre Yekedüz explained.

Patients receiving ICIs were associated with a greater risk of developing RA, but lower risks for SLE and SSc.

Clinical characteristics were associated with different survival outcomes in patients treated with immune checkpoint ...

Cutaneous melanoma, the most aggressive form of skin cancer, is characterized by its accumulation of a large number of ...

Final phase 2a results showed that CAN-2409 led to a median overall survival of 24.5 months in immune checkpoint ...

A team of researchers from Cleveland Clinic Genomic Medicine share insights from an early set of 19,000 patients to receive immune checkpoint inhibitor treatments for colorectal cancer in the U.S.

Antitumor activity observed with confirmed partial responses in 50% of patientsat highest dose tested to date, across ...